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facilitate rapid implementation of the interven-
tion in large numbers of patients by the clinical 
staff at different institutions, all in the chaos of 
emergency departments; and to avoid potential 
responder bias in the outcome assessments of 
patients (or surrogates) who may have thought 
they had received “nonstandard” care. Our deci-
sion to view the matter of head position as involv-
ing “low risk” was based on several consider-
ations: the insufficient amount of level 1 evidence 
specifying the benefits and harms of head posi-
tioning for patients with acute stroke; the fact 
that people change their head position within 
the ranges being tested during routine hospital 
care and in daily life, as they shift from activity 
during the day to rest and sleep at night; and the 
view that patient care would not be compromised 
by either of the interventions.
Finally, Taito and Yamauchi raise an important 
point regarding an unresolved issue that should 
be addressed in another trial — that of the ap-
propriate timing (and intensity) of early mobili-
zation after acute stroke that follows from the 
unexpected results of the AVERT trial.2 Unfortu-
nately, we did not collect data on the specific 
time that patients began to move outside the 
confines of the bed.
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Transplanting HCV-Infected Kidneys into Uninfected Recipients
To the Editor: Goldberg et al. (June 15 issue)1 
report cure of hepatitis C virus (HCV) infection, 
after transplantation of kidneys infected with 
HCV (genotype 1) into HCV-negative recipients, 
with the use of a 12-week course of elbasvir–
grazoprevir. However, data on other types of 
solid-organ transplantation are lacking. Here, we 
report cure of HCV infection after accidental 
transmission of HCV from one organ donor to 
five different recipients (Table 1). The 55-year-old 
female donor did not belong to a group consid-
ered to be at high risk for HCV infection, and 
routine testing for anti-HCV IgG was negative. 
However, retrospective analysis revealed low-
level HCV RNA (genotype 1a) viremia. All the 
transplant recipients were HCV-negative before 
transplantation and had development of HCV 
viremia in the early post-transplantation period. 
A 12-week course of different sofosbuvir-based 
anti-HCV regimens2-4 was used to treat four of 
the patients. The liver-transplant recipient died 
from septic shock early after transplantation, be-
fore treatment could have been initiated. All four 
recipients who received treatment currently have 
stable graft function and cure of HCV infection 
(sustained virologic response at week 12 after 
treatment).
In summary, we contribute further evidence 
that the early initiation of a sofosbuvir-based 
regimen is an efficient and safe treatment op-
tion in the context of different types of solid-
organ transplantation from an HCV-positive donor 
to an HCV-negative recipient.
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To the Editor: Goldberg and colleagues demon-
strated that HCV-positive kidneys can be success-
fully used for transplantation in HCV-negative 
recipients. Likewise, the livers of many HCV-pos-
itive donors are of good quality and can be trans-
planted, with outcomes similar to those obtained 
with HCV-negative livers. In 2015, however, 11% 
of procured HCV-positive livers were discarded.1 
The new direct-acting antiviral agents have dra-
matically changed the landscape of HCV treat-
ment, with sustained virologic response rates of 
up to 95%, independent of HCV genotype, stage 
of fibrosis, or previous response to antiviral ther-
apy.2,3 The use of HCV-positive livers could sub-
stantially decrease waiting time and mortality 
among HCV-negative patients on the transplant 
waiting list. Clinical trial data on intentional 
transplantation of HCV-positive livers into HCV-
negative recipients are lacking. HCV-negative pa-
tients who have, without the knowledge of the 
physician, received HCV-positive livers have had 
good responses to treatment.4 In our center, we 
have successfully performed two intentional trans-
plantations of HCV-positive livers into HCV-neg-
ative recipients. In light of the new HCV treatment 
options available, it is unethical to let HCV-neg-
ative patients die while many usable HCV-positive T
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liver grafts are discarded. It is now time to chal-
lenge dogmatic beliefs and the current trans-
plant-allocation algorithm.
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The authors reply: Halleck et al. describe five 
patients who were infected with HCV after trans-
plantation with organs from a deceased donor in 
whom HCV infection had not been suspected. 
Four recipients survived the early post-transplan-
tation period and were cured of HCV infection. 
Their experience adds to the small but growing 
body of evidence indicating that transplantation-
related immunosuppression does not substan-
tially diminish the effectiveness of direct-acting 
antiviral agents for HCV treatment.1 The donor’s 
profile also offers a cautionary tale: risk stratifi-
cation for bloodborne viral infections has limited 
value, because this stratification is based on 
whatever information happens to be available 
about the donor’s social and medical history. We 
advocate that all organ donors undergo nucleic 
acid screening for HCV and HIV infection, which 
is more sensitive than antibody testing and has 
enhanced relevance during this era of widespread 
and sometimes unsuspected opiate abuse in many 
places, including the United States.2
Martins et al. report two instances in which 
HCV-infected livers were intentionally used for 
transplantation into HCV-negative recipients. We 
support continued study of this practice, which 
we believe should not yet be the standard of 
care. Research oversight is appropriate. Most can-
didates for transplantation know little about HCV. 
The risks of complications and noncure after new 
HCV transmission during transplantation are un-
certain. Therefore, robust processes of informed 
consent that acknowledge the unknown magni-
tude of risks are needed. Centers should collabo-
rate, develop best practices, and publish on their 
experience with transplanting HCV-infected or-
gans into HCV-negative patients.3
The biggest impediment to expanding the use 
of HCV-infected organs in some nations is guar-
anteeing access to expensive antiviral therapy. 
Leaders of transplantation programs and profes-
sional societies must work with payers to prospec-
tively authorize treatment, so that patients who 
consent to donor-derived HCV infection are as-
sured of timely therapy. In addition, the selec-
tion of antiviral therapy requires consideration 
of the viral genotype and interactions with com-
monly used drugs after transplantation. Renal in-
sufficiency is also common with transplantation, 
and this may complicate the safe use of anti-
virals, including sofosbuvir; acute kidney injury 
occurs among more than a third of liver-trans-
plant recipients specifically.4 Although we are 
optimistic that HCV-infected organs will expand 
the donor pool substantially, more data are need-
ed to define the safest and most effective use of 
these organs for recipients who do not have HCV 
infection.
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